LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

Autor:	S-B. Kim, Wasat Mansoor, Qi Liu, M.A. Maqueda, Eray Goekkurt, Liang Shen, Pooja Bhagia, Kyoko Kato, Manish A. Shah, Antoine Adenis, Patrapim Sunpaweravong, Takashi Kojima, J.-P. Metges, B.C. Chul Cho, Peter C. Enzinger, Sukrut Shah, J-M. Sun, Toshihiko Doi, S-H. Li, Zhigang Li
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Hematology Pembrolizumab First line therapy Internal medicine Advanced esophageal cancer Medicine In patient business
Zdroj:	Annals of Oncology. 31:S1192-S1193
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a6757ca5a9909874dc75bd7b2830924e https://doi.org/10.1016/j.annonc.2020.08.2298 Zobrazit plný text záznamu